CD52 expression in peripheral T-cell lymphomas determined by combined immunophenotyping using tumor cell specific T-cell receptor antibodies

References

• Rudiger T, Weisenburger D D, Anderson J R, Armitage J O, Diebold J, MacLennan K A, et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140–149
   PubMed Web of Science ®Google Scholar
• Swerdlow, S H, Campo, E, Harris, N L, Jaffe, E S. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press. 2008
   Google Scholar
• Reimer P, Schertlin T, Rudiger T, Geissinger E, Roth S, Kunzmann V, et al. Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. Hematol J 2004; 5: 304–311
   PubMedGoogle Scholar
• Gallamini A, Zaja F, Patti C, Billio A, Specchia M R, Tucci A, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 2007; 110: 2316–2323
   PubMed Web of Science ®Google Scholar
• Morris J C, Waldmann T A, Janik J E. Receptor-directed therapy of T-cell leukemias and lymphomas. J Immunotoxicol 2008; 5: 235–248
   PubMed Web of Science ®Google Scholar
• Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006; 20: 1533–1538
   PubMed Web of Science ®Google Scholar
• Hale G, Xia M Q, Tighe H P, Dyer M J, Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118–127
   PubMed Web of Science ®Google Scholar
• Gilleece M H, Dexter T M. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807–812
   PubMed Web of Science ®Google Scholar
• Rowan W C, Hale G, Tite J P, Brett S J. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995; 7: 69–77
   PubMed Web of Science ®Google Scholar
• Xia M Q, Hale G, Lifely M R, Ferguson M A, Campbell D, Packman L, Waldmann H. Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 1993; 293(Part 3)633–640
   PubMed Web of Science ®Google Scholar
• Treumann A, Lifely M R, Schneider P, Ferguson M A. Primary structure of CD52. J Biol Chem 1995; 270: 6088–6099
   PubMed Web of Science ®Google Scholar
• Hederer R A, Guntermann C, Miller N, Nagy P, Szollosi J, Damjanovich S, et al. The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells. Int Immunol 2000; 12: 505–516
   PubMed Web of Science ®Google Scholar
• Ratzinger G, Reagan J L, Heller G, Busam K J, Young J W. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation. Blood 2003; 101: 1422–1429
   PubMed Web of Science ®Google Scholar
• Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–327
   PubMed Web of Science ®Google Scholar
• Greenwood J, Clark M, Waldmann H. Structural motifs involved in human IgG antibody effector functions. Eur J Immunol 1993; 23: 1098–1104
   PubMed Web of Science ®Google Scholar
• Xia M Q, Hale G, Waldmann H. Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol Immunol 1993; 30: 1089–1096
   PubMed Web of Science ®Google Scholar
• Nuckel H, Frey U H, Roth A, Duhrsen U, Siffert W. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol 2005; 514: 217–224
   PubMed Web of Science ®Google Scholar
• Dyer M J, Hale G, Hayhoe F G, Waldmann H. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood 1989; 73: 1431–1439
   PubMed Web of Science ®Google Scholar
• Rowan W, Tite J, Topley P, Brett S J. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology 1998; 95: 427–436
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, Mellstedt H. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Gupta V, Ball S E, Yi Q L, Sage D, McCann S R, Lawler M, et al. Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. Biol Blood Marrow Transplant 2004; 10: 867–876
   PubMed Web of Science ®Google Scholar
• Khorana A, Bunn P, McLaughlin P, Vose J, Stewart C, Czuczman M S. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 41: 77–87
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16: 3257–3263
   PubMed Web of Science ®Google Scholar
• Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol 2006; 33: S44–S52
   PubMed Web of Science ®Google Scholar
• Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald A P, Repp R, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 2004; 103: 2920–2924
   PubMed Web of Science ®Google Scholar
• Uppenkamp M, Engert A, Diehl V, Bunjes D, Huhn D, Brittinger G. Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study. Ann Hematol 2002; 81: 26–32
   PubMed Web of Science ®Google Scholar
• Perez-Simon J A, Kottaridis P D, Martino R, Craddock C, Caballero D, Chopra R, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 2002; 100: 3121–3127
   PubMed Web of Science ®Google Scholar
• Dearden C E, Matutes E, Catovsky D. Alemtuzumab in T-cell malignancies. Med Oncol 2002; 19(Suppl)S27–S32
   PubMed Web of Science ®Google Scholar
• Chang S T, Lu C L, Chuang S S. CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma 2007; 48: 117–121
   PubMed Web of Science ®Google Scholar
• Piccaluga P P, Agostinelli C, Righi S, Zinzani P L, Pileri S A. Expression of CD52 in peripheral T-cell lymphoma. Haematologica 2007; 92: 566–567
   PubMed Web of Science ®Google Scholar
• Miles R R, Cairo M S, Satwani P, Zwick D L, Lones M A, Sposto R, et al. Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. Br J Haematol 2007; 138: 506–512
   PubMed Web of Science ®Google Scholar
• Rodig S J, Abramson J S, Pinkus G S, Treon S P, Dorfman D M, Dong H Y, et al. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H). Clin Cancer Res 2006; 12: 7174–7179
   PubMed Web of Science ®Google Scholar
• Geissinger E, Bonzheim I, Krenacs L, Roth S, Strobel P, Ott G, et al. Identification of the tumor cells in peripheral T-cell lymphomas by combined polymerase chain reaction-based T-cell receptor beta spectrotyping and immunohistological detection with T-cell receptor beta chain variable region segment-specific antibodies. J Mol Diagn 2005; 7: 455–464
   PubMed Web of Science ®Google Scholar
• Bonzheim I, Geissinger E, Roth S, Zettl A, Marx A, Rosenwald A, et al. Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling. Blood 2004; 104: 3358–3360
   PubMed Web of Science ®Google Scholar
• Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer M J, Catovsky D. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185–191
   PubMed Web of Science ®Google Scholar
• Jiang L, Yuan C M, Hubacheck J, Janik J E, Wilson W, Morris J C, et al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009; 145: 173–179
   PubMed Web of Science ®Google Scholar